Product Description
Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Aleglitazar binds to both PPARalpha and PPARgamma and decreases plasma levels of glucose, LDL-C, triglycerides (TG) and increases HDL levels. This agent may be used for the treatment of diabetes and cardiovascular disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Aleglitazar)
Mechanisms of Action: PPAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Failure, Chronic|Acute Coronary Syndrome|Type 2 Diabetes
Phase 2: Kidney Diseases|Heart Failure|Type 2 Diabetes|Myocardial Ischemia|Coronary Artery Disease|Insulin Resistance
Phase 1: Healthy Volunteers|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Alerenal Study | P3 |
Withdrawn |
Type 2 Diabetes|Kidney Failure, Chronic |
2019-01-01 |
|
| YC28037 | P3 |
Completed |
Type 2 Diabetes |
2013-11-01 |
|
| BC22140 | P3 |
Completed |
Type 2 Diabetes|Acute Coronary Syndrome |
2013-11-01 |
|
| BC28027 | P3 |
Completed |
Type 2 Diabetes |
2013-11-01 |